Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Adma Biologics (ADMA) Long-Term Debt Issuances: 2011-2023

Historic Long-Term Debt Issuances for Adma Biologics (ADMA) over the last 1 years, with Dec 2023 value amounting to $135.0 million.

  • Adma Biologics' Long-Term Debt Issuances was N/A to $135.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $314.2 million, marking a year-over-year change of. This contributed to the annual value of $135.0 million for FY2023, which is 11.04% down from last year.
  • Latest data reveals that Adma Biologics reported Long-Term Debt Issuances of $135.0 million as of Q4 2023, which was down 11.04% from $151.8 million recorded in Q1 2022.
  • Adma Biologics' Long-Term Debt Issuances' 5-year high stood at $151.8 million during Q1 2022, with a 5-year trough of $12.5 million in Q1 2020.
  • Moreover, its 2-year median value for Long-Term Debt Issuances was $143.4 million (2022), whereas its average is $143.4 million.
  • Data for Adma Biologics' Long-Term Debt Issuances shows a maximum YoY crashed of 72.22% (in 2020) over the last 5 years.
  • Over the past 4 years, Adma Biologics' Long-Term Debt Issuances (Quarterly) stood at $45.0 million in 2019, then slumped by 72.22% to $15.0 million in 2020, then reached $151.8 million in 2022, then reached $135.0 million in 2023.
  • Its Long-Term Debt Issuances stands at $135.0 million for Q4 2023, versus $151.8 million for Q1 2022 and $15.0 million for Q4 2020.